eXmoor News and Resources

eXmoor Pharma, a contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy (CGT), has partnered with Virica Biotech in a project aimed at improving the manufacture of adeno-associated vectors (AAVs), a vital component of gene therapies. Funded

Quell Therapeutics Ltd and eXmoor pharma have announced a strategic partnership to manufacture Quell’s autologous CAR-Treg cell therapies, aimed at treating autoimmune diseases. The agreement covers process transfer, scale-out, and Phase 1/2 clinical manufacturing for multiple candidates in Quell’s pipeline.